reviewAmerican Journal of HematologyMar 12, 2019BRONZE OA

Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment

Fox Chase Cancer Center · University of Pennsylvania

PubMed
Indexed incrossrefpubmed

Abstract

DISEASE OVERVIEW: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma originating from the germinal center, and it represents a heterogeneous group of diseases with variable outcomes that are differentially characterized by clinical features, cell of origin (COO), molecular features, and most recently, frequently recurring mutations. DIAGNOSIS: DLBCL is ideally diagnosed from an excisional biopsy of a suspicious lymph node, which shows sheets of large cells that disrupt the underlying structural integrity of the follicle center and stain positive for pan-B-cell antigens, such as CD20 and CD79a. COO is determined by immunohistochemical stains, while molecular…

Citation impact

503
total citations
FWCI
37.95
Percentile
100%
References
93
Citations per year

Authors

2

Topics & keywords

Keywords
  • BCL6
  • Chemoimmunotherapy
  • International Prognostic Index
  • Germinal center
  • Diffuse large B-cell lymphoma
  • Medicine
  • Lymphoma
  • Rituximab
UN Sustainable Development Goals
  • No poverty
No related works found for this paper.